Parschauer Karah Herdman 4

What Happened Karah Herdman, Executive Vice President and Chief Legal Officer of Ultragenyx Pharmaceutical Inc. (RARE), sold 1,899 shares in an open-market/private sale on June 15, 2026. The shares were sold at $24.62 each for a total reported proceeds of $46,753. This was a sale (code S) — routine insider sales are common and do not necessarily indicate the insider's view of the company.

Key Details

• Transaction date: 2026-06-15
• Transaction type: Sale (S), open market/private sale
• Shares sold: 1,899 at $24.62 per share; total proceeds $46,753
• Shares owned after transaction: Not disclosed in the information provided
• Filing/accession: Form 4 filed 2026-06-15 (Accession 0001677455-26-000002); filing appears same day as the reported transaction
• Footnotes:
  • F1: Includes 646 shares acquired under the Company’s Amended and Restated Employee Stock Purchase Plan on April 30, 2026.
  • F2: Includes previously reported shares underlying RSUs granted to the reporting person that remain subject to certain vesting conditions.

Context This report reflects a straightforward sale by an officer. Sales by executives can be for many personal reasons (diversification, taxes, etc.) and are not definitive indicators of company prospects. No option exercises, gifts, or other derivative transactions were reported in this filing excerpt.